Loading... Please wait...
Sort by:
  • Market Access Impact: Growth Hormone Deficiency (EU5) 2017
    Learn More Market Access Impact: Growth Hormone Deficiency (EU5) 2017
    Market barriers may be costing you share, but perception could be the bigger problem Market barriers affect nearly 25% of growth hormone prescriptions in the EU5 countries. Most brands lose market share because of them,...
  • Market Access Impact: Growth Hormone Deficiency (US) 2017
    Learn More Market Access Impact: Growth Hormone Deficiency (US) 2017
    What stops doctors from prescribing your brand? It may be more than one thing Market barriers affect over 20% of growth hormone prescriptions in the US, and most brands lose market share because of them. According to...
  • Market Access Impact: Renal Cell Carcinoma (EU5) 2017
    Learn More Market Access Impact: Renal Cell Carcinoma (EU5) 2017
    Eliminating market barriers could help one brand almost double its market share Market barriers have a modest but significant effect on renal cell carcinoma (RCC) prescriptions in the EU5. The brands that can find a way...
  • Market Access Impact: Renal Cell Carcinoma (US) 2017
    Learn More Market Access Impact: Renal Cell Carcinoma (US) 2017
    Who wins when high costs drag the leading brand down? Market barriers affect nearly a quarter of renal cell carcinoma (RCC) prescriptions in the US. High costs especially are preventing oncologists we surveyed from...
  • Real World Data: Meeting Payer Needs
    Learn More Real World Data: Meeting Payer Needs
    How to adjust your Real World Data provision to address the real needs of payers Drug costs are spiralling upwards and so too are frustration levels. Payers with stretched budgets are still struggling to make the case...
  • How Payers Want to Work With Pharma
    Learn More How Payers Want to Work With Pharma
    How to effectively engage US and EU payers You’re speaking to payers, but are they listening?  Do you really understand their needs and concerns?  Is your approach to payer negotiations getting your...
  • Pulling the Data Puzzle Together: Being Payer-Centric
    Learn More Pulling the Data Puzzle Together: Being Payer-Centric
    Mapping data with payer needs. How to solve the data puzzle.  Everyone is talking about data. What’s being collected; how robust is it; what does it prove; who should be told? From the all-important payer...
  • Charting the Orphan Drug Development Pipeline
    Learn More Charting the Orphan Drug Development Pipeline
    Which are the most exciting areas of orphan drug research and where are the best opportunities? Global sales of drugs for orphan indications were estimated to be $114 billion in 2016, with sales forecast to rise to $209...
  • Market Access Impact: HIV (EU5) 2017
    Learn More Market Access Impact: HIV (EU5) 2017
    HIV drug market barriers: A help or a hindrance? Today’s tightly packed European HIV drug landscape is the culmination of numerous innovative developments over the last three decades. New market entrants continue...
  • Market Access Impact: HIV (US) 2017
    Learn More Market Access Impact: HIV (US) 2017
    Are US market barriers helping or hindering your HIV brand? Today’s tightly packed US HIV drug landscape is the culmination of numerous innovative developments over the last three decades. New market entrants...
  • Market Access Impact: Psoriasis (EU5) 2017
    Learn More Market Access Impact: Psoriasis (EU5) 2017
    Eliminating market barriers could lift the last place brand into the middle of the pack In the EU5 countries, market barriers affect nearly a quarter of psoriasis prescriptions. Most of the brands we surveyed gain or...
  • Market Access Impact: Psoriasis  (US) 2017
    Learn More Market Access Impact: Psoriasis (US) 2017
    Top brand takes a big lead thanks to market barriers In the US, market barriers are having a major impact on the brands used to treat psoriasis—affecting more than a third of all prescriptions and helping some...
  • Real World Data Capabilities: Benchmarking Pharma Companies
    Learn More Real World Data Capabilities: Benchmarking Pharma Companies
    Is Real World Data giving your market access the power charge it needs? Real World Data (RWD) and Real World Evidence (RWE) are gaining traction across the industry. The front runners are already exploring new ways to...
  • Market Access Impact: Melanoma  (EU5) 2017
    Learn More Market Access Impact: Melanoma (EU5) 2017
    Two brands are neck and neck for 2nd place. Would eliminating barriers break the tie? In the EU5, market barriers affect nearly a quarter of all melanoma prescriptions, giving the top brand a narrow lead over two rivals...
  • Market Access Impact: Melanoma (US) 2017
    Learn More Market Access Impact: Melanoma (US) 2017
    Market barriers affect over a quarter of melanoma prescriptions. Is your brand losing out? In the US, where market barriers affect more than a quarter of all melanoma prescriptions, the top brand has a narrow lead over...
  • Overcoming Market Access Barriers to High Value Drugs
    Learn More Overcoming Market Access Barriers to High Value Drugs
    Overcoming market access barriers to high-value drugs How can you breakthrough the market access barriers that face high-value oncology and immunotherapy products in the EU5 and US? Pharma faces unprecedented demands...

customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved